Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

Inclusion Criteria: * male/female between 50 and 89 years (inclusive) * declining cognitive function of at least 3 months duration interfering with complex activities of daily living * normal basic activities of daily independent living * Clinical Dementia Rating scale score equal to 0.5 * score at least one point above the lowest possible score on 7 out of 8 tests in the cognitive battery at both Selection Visit and Baseline Visit Exclusion Criteria: * general anesthetics within 3 months of selection visit * history of severe allergic drug reaction(s) * history of drug or alcohol dependence (DSM IV defined) within the last 12 months * any drug prescribed to activate cerebral metabolism, taken within 1 week of screening or/and concomitantly * concomitant intake of anticoagulent medications * concomitant intake or intake within 1 week before screening of drug that might affect cognitive function or central nervous system * history of dementia, psychiatric or neurological disorders, mental retardation, learning disabilities and stroke * current depression * impaired renal function, thyroid function or neurological degeneration * any gastrointestinal dysfunction that might interfere with the absorption or elimination of the study drug * insulin-dependant diabetes mellitus * bleeding disorders or disturbance in hemostatic function.